^
Association details:
| Biomarker: | BRAF wild-type |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Published date:
11/17/2021
Excerpt:
...the phase 1/2 KEYNOTE-022 study investigated the maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours and BRAF wild-type melanoma.....ORR was 40% in concurrent DL1 and 0% in concurrent DL2b….ORR in intermittent DL1 was 33%....The combination had limited antitumour activity, numerically higher ORR with intermittent versus concurrent dosing, and manageable safety.
DOI:
https://doi.org/10.1016/j.ejca.2021.09.024
Trial ID:
